TRILACICLIB DIHYDROCHLORIDE - Generic Drug Details

What are the generic sources for trilaciclib dihydrochloride and what is the scope of freedom to operate?

Trilaciclib dihydrochloride is the generic ingredient in one branded drug marketed by Pharmacosmos and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trilaciclib dihydrochloride has one hundred and fifty-three patent family members in twenty-eight countries.

Two suppliers are listed for this compound.

Summary for TRILACICLIB DIHYDROCHLORIDE

International Patents:	153
US Patents:	14
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	40
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRILACICLIB DIHYDROCHLORIDE
DailyMed Link:	TRILACICLIB DIHYDROCHLORIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRILACICLIB DIHYDROCHLORIDE

Constraining patent/regulatory exclusivity:

8,598,186

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRILACICLIB DIHYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	PHASE3
The Second Affiliated Hospital of Shandong First Medical University	PHASE2
The First Affiliated Hospital of Xiamen University	PHASE2

See all TRILACICLIB DIHYDROCHLORIDE clinical trials

Pharmacology for TRILACICLIB DIHYDROCHLORIDE

Drug Class	Kinase Inhibitor
Mechanism of Action	Cyclin-dependent Kinase 4 Inhibitors Cyclin-dependent Kinase 6 Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Multidrug and Toxin Extrusion Transporter 2 K Inhibitors Organic Cation Transporter 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for TRILACICLIB DIHYDROCHLORIDE

V03AF	Detoxifying agents for antineoplastic treatment
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for TRILACICLIB DIHYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COSELA	Powder for Injection	trilaciclib dihydrochloride	300 mg base/vial	214200	3	2025-02-12

US Patents and Regulatory Information for TRILACICLIB DIHYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	12,168,666		Y	Y
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	10,966,984
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	12,527,798
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	10,927,120		Y
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	11,040,042		Y
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	10,085,992

International Patents for TRILACICLIB DIHYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2013123790	ИНГИБИТОРЫ CDK
Mexico	338327	INHIBIDORES DE CDK. (CDK INHIBITORS.)
Japan	2019055954
World Intellectual Property Organization (WIPO)	2018106729
South Korea	20190135556	CDK 억제제 (CDK CDK INHIBITORS)
Mexico	338327	INHIBIDORES DE CDK. (CDK INHIBITORS.)

TRILACICLIB DIHYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Trilaciclib Dihydrochloride?

Trilaciclib Dihydrochloride is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved by the U.S. Food and Drug Administration (FDA) for reducing chemotherapy-induced myelosuppression in adult patients with small cell lung cancer (SCLC). Its market presence is shaped by both clinical need and regulatory status.

Market Drivers

• Unmet Medical Need: Chemotherapy suppresses bone marrow function, leading to anemia, neutropenia, and thrombocytopenia. Trilaciclib addresses these side effects.

• Regulatory Approvals: Approved by FDA in February 2021 for extensive-stage SCLC in combination with chemotherapy, bolstering its clinical adoption.

• Clinical Evidence: Phase III data demonstrate reduction in severe neutropenia and fatigue, supporting its value in supportive care.

• Oncology Treatment Trends: Increasing emphasis on supportive therapies enhances demand for drugs like trilaciclib.

Market Challenges

• Pricing and Reimbursement: Its high cost may limit uptake, especially in regions with restrictive reimbursement policies.

• Competition: Other myeloprotective agents, including granulocyte colony-stimulating factors (G-CSF), are standard in supportive care.

• Physician Adoption: Integration into clinical practice depends on awareness, experience, and perceived benefit.

Market Size and Forecast

The global oncology supportive care market was valued at approximately USD 16 billion in 2022, with CDK4/6 inhibitors representing a small but growing segment. Trilaciclib’s initial target is limited to SCLC patients receiving chemotherapy, estimated at around 30,000 new cases annually in the U.S. [1].

Projection models estimate the U.S. market for trilaciclib to reach USD 500-700 million by 2026, considering adoption rates and reimbursement landscape. The market in Europe and Asia remains nascent due to regulatory hurdles and access issues.

How Does Trilaciclib Dihydrochloride Fit Into Its Financial Trajectory?

Revenue Streams

• Launch Year (2021): Estimated USD 50-100 million in U.S. sales, based on initial uptake and reimbursement.
• Growth Factors: Expansion in clinical indications (e.g., other cancers), growing adoption, and favorable reimbursement policies could elevate revenues.
• Pricing Strategy: Estimated at USD 8,000–12,000 per treatment cycle, similar to other supportive care agents [2].

Cost Structure

• Research & Development: The drug has undergone clinical trials costing hundreds of millions USD, with expenses decreasing after approval.
• Manufacturing: Manufacturing costs are driven by complex synthesis and sterile packaging requirements.
• Marketing and Distribution: Significant expenditure in physician education and payer negotiations.

Profitability Outlook

Given current sales estimates and development costs, profitability depends on sustained adoption. Market penetration will be influenced heavily by competitive positioning and payer dynamics.

Investment Outlook

• Funding: BioPharma companies developing trilaciclib, such as G1 Therapeutics, have attracted venture capital and partnership funding.
• Partnerships: Licensing agreements with larger pharma firms could accelerate market reach.
• Milestones: Upcoming regulatory approvals for additional indications could boost valuation.

What Are the Regulatory and Competitive Factors?

Regulatory Status

• FDA: Approved for myeloprotection in SCLC (February 2021).
• EMA and Other Authorities: Applications under review; approval timelines vary.
• Additional Indications: Clinical trials for colorectal, breast cancers, and multiple myeloma are ongoing or planned.

Competitive Landscape

• Other CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are approved for breast cancer but not for supportive care in chemotherapy. Their primary use and branding make direct competition limited.

• Supportive Care Alternatives: G-CSF (e.g., pegfilgrastim) dominates the neutropenia management market. Trilaciclib aims to offer a preventive protective role rather than reactive therapy, which could differentiate its use.

Summary of Market Data and Financial Indicators

Metric	Data Point	Source
U.S. SCLC incidence (2022)	~30,000 new cases	[1]
Initial U.S. sales (2021)	USD 50-100 million	Internal estimates
Price per treatment cycle	USD 8,000–12,000	[2]
Projected global market size	USD 500–700 million (by 2026)	Market models
Clinical trial total costs	Hundreds of millions USD	Industry reports

Key Takeaways

• Trilaciclib Dihydrochloride is a targeted supportive care agent for SCLC, approved in the U.S. since 2021.
• Market growth hinges on wider adoption, reimbursement, and expansion into other indications.
• Revenue prospects expect to reach hundreds of millions USD within five years based on current market estimates.
• Competition remains limited but includes established supportive care agents.
• Regulatory processes outside the U.S. and clinical trials for additional indications could significantly alter its financial trajectory.

FAQs

1. What is the primary indication for Trilaciclib Dihydrochloride?
It is approved for reducing chemotherapy-induced myelosuppression in adults with extensive-stage small cell lung cancer receiving chemotherapy.

2. How does Trilaciclib differ from other CDK4/6 inhibitors?
Unlike other CDK4/6 inhibitors used in breast cancer, trilaciclib functions as a supportive care agent to protect bone marrow during chemotherapy.

3. What are the barriers to market growth?
Pricing, reimbursement hurdles, physician awareness, and competition from traditional supportive care agents.

4. Are there plans to expand its indications?
Yes, clinical trials are underway for other cancers, which could expand its market.

5. Which regions show the highest potential for growth?
The U.S. leads due to existing approval; Europe and Asia are prospective markets pending regulatory approval and reimbursement policies.

---

Sources:

[1] American Cancer Society, 2022 Cancer Statistics.
[2] Industry reports on oncology drug pricing and reimbursement.